阿片类药物处方与不同eGFR范围内死亡及住院风险的关联
该研究在2008至2017年间纳入Geisinger Health成年初级保健患者,将首次接受阿片类处方者与接受NSAIDs者进行倾向性匹配,比较死亡和住院风险,并按随时间变化的eGFR和每日口服吗啡毫克当量(MME)分层分析。结果显示,与NSAIDs相比,阿片类处方与更高的死亡和住院风险相关,且在高剂量和较低eGFR时风险更高。
要点
- 与NSAIDs相比,阿片类处方1-59和≥60 MME与死亡和住院风险升高相关。
- ≥60 MME与死亡风险的关联在较低eGFR时更强(交互P=0.01)。
- 以加巴喷丁类药物为对照时,仅≥60 MME与死亡风险显著相关,但两种剂量均与住院风险相关。
核心结论
- 处方阿片类药物与其他止痛药相比与更高的死亡和住院风险相关,尤其在高剂量和较低eGFR时。
研究设计与样本
- 研究人群为2008至2017年Geisinger Health(宾夕法尼亚州丹维尔)的成年初级保健患者。
- 将首次接受阿片类处方者与接受NSAIDs者进行倾向性匹配,并在敏感性分析中与加巴喷丁类药物比较。
- 倾向性匹配队列包括46,246名在2008至2017年间被处方阿片类或NSAIDs的患者(平均[SD]年龄54[16]岁;56%女性;3%黑人种族)。
- 阿片类药物暴露按随时间变化的每日口服吗啡毫克当量(MMEs)分类,并在随时间变化的eGFR下评估。
主要发现
- 在eGFR 80 ml/min per 1.73 m2时,与NSAIDs处方相比,1-59 MMEs与死亡风险升高相关(HR 1.70;95% CI 1.41至2.05),≥60 MMEs与死亡风险升高相关(HR 2.25;95% CI 1.82至2.79)。
- 在eGFR 80 ml/min per 1.73 m2时,与NSAIDs处方相比,1-59 MMEs与住院风险升高相关(HR 1.38;95% CI 1.30至1.46),≥60 MMEs与住院风险升高相关(HR 1.68;95% CI 1.56至1.81)。
- ≥60 MMEs与死亡风险的相对风险在较低GFR时更高(例如eGFR 40 ml/min per 1.73 m2;HR 3.94;95% CI 2.70至5.75;交互P=0.01)。
- 以加巴喷丁类药物为对照药物时,仅≥60 MMEs与死亡风险升高显著相关(HR 2.72;95% CI 1.71至4.34),但1-59和≥60 MMEs均与住院风险相关(1-59 MMEs:HR 1.22;95% CI 1.04至1.43;≥60 MMEs:HR 1.54;95% CI 1.28至1.86)。
临床怎么用
- 在肾内科患者中处方阿片类药物时,应关注剂量和eGFR,尤其是高剂量(≥60 MME)和较低eGFR时死亡风险更高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Most opioids undergo kidney excretion. The goal of this study was to evaluate opioid-associated risks of death and hospitalization across the range of eGFR. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The study population included adult primary care patients in Geisinger Health (Danville, PA) between 2008 and 2017. People receiving their first opioid prescription were propensity matched to people receiving NSAIDS (and, in sensitivity analysis, gabapentinoids) and the risk of death and hospitalization were compared, classifying opioid medication exposure as time-varying daily oral morphine milligram equivalents (MMEs) across time-varying eGFR. RESULTS: The propensity-matched cohort included 46,246 patients prescribed either opioids or NSAIDs between 2008 and 2017 (mean [SD] age, 54 [16] years; 56% female; 3% of black race). Prescriptions for 1-59 and ≥60 MMEs were associated with higher risk of death (HR, 1.70; 95% CI, 1.41 to 2.05 for 1-59 MMEs; HR, 2.25; 95% CI, 1.82 to 2.79 for ≥60 MMEs) and hospitalization (HR, 1.38; 95% CI, 1.30 to 1.46 for 1-59 MMEs; HR, 1.68; 95% CI, 1.56 to 1.81 for ≥60 MMEs) compared with NSAID prescriptions, when evaluated at eGFR 80 ml/min per 1.73 m2. The relative risk of death associated with ≥60 MMEs was higher at lower GFR (e.g., eGFR, 40 ml/min per 1.73 m2; HR, 3.94; 95% CI, 2.70 to 5.75; P for interaction, 0.01). When gabapentinoids were used as the comparison medication, only ≥60 MMEs were significantly associated with higher risk of death (HR, 2.72; 95% CI, 1.71 to 4.34), although both 1-59 and ≥60 MMEs were associated with risk of hospitalization (HR, 1.22; 95% CI, 1.04 to 1.43 for 1-59 MMEs; HR, 1.54; 95% CI, 1.28 to 1.86 for ≥60 MMEs). CONCLUSIONS: The receipt of prescription opioids was associated with a higher risk of death and hospitalization compared with other pain medications, particularly with higher doses and at lower eGFR.
引用
- Novick TK, Surapaneni A, Shin JI, et al. Associations of Opioid Prescriptions with Death and Hospitalization across the Spectrum of Estimated GFR. Clin J Am Soc Nephrol. 2019. PMID: 31582462. doi:10.2215/CJN.00440119
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。